HEALTH & WELLNESS
ICMR seeks private partners to jointly develop and commercialize new typhoid and paratyphoid vaccines through Expression of Interest.
By Aniket Chakraborty
Feb 19, 2025
Arrow
Arrow
Research foundation laid at ICMR-NIRBI Kolkata, where scientists discovered potential vaccine development from pathogen outer membrane structures.
2
Arrow
Selected companies must pay 2% royalty on net sales according to ICMR's Technology Development Collaboration guidelines.
3
Arrow
Three key pathogens targeted: Salmonella Typhi, Salmonella Paratyphi, and Salmonella Typhimurium.
4
Arrow
ICMR promises expert guidance and technical support throughout all phases of vaccine production.
5
Arrow
Companies will be evaluated based on their R&D plans, facilities, and capabilities before partnership.
6
Arrow
India recorded highest global typhoid cases in 2021 - approximately 1 crore cases, per CMC Vellore and ICMR study.
7
Arrow
Partners will handle both validation of vaccine technology and commercialization aspects.
8
Arrow
India currently has a WHO-approved indigenous Vi-TT conjugate vaccine for typhoid.
9
The initiative aims to reduce India's typhoid burden through improved treatment options.
10